Dihydroorotate dehydrogenase inhibitors for the treatment of...

Details Dihydroorotate dehydrogenase inhibitors for the treatment of... Dihydroorotate dehydrogenase inhibitors for the treatment of...

2005-01-11

2005-01-11

Seaman, D. Margaret (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S165000, C546S170000, C546S178000

Reexamination Certificate

active

06841561

ABSTRACT:
Flavivirus, rhabdovirus and paramyxovirus infections may be treated by administering an inhibitor of the enzyme dihydroorotate dehydrogenase such as 6-fluoro-2-(2′-fluoro-1,1′-biphenyl-4-yl)-3-methyl-4-quinolinearcarboxylic acid sodium salt (Brequinar). A synergistic effect can be obtained if an interferon such as interferon α2, interferon α8 or interferon β, or an inhibitor of a second enzyme selected from inosine monophosphate dehydrogenase, guanosine monophosphate synthetase, cytidine triphosphate synthetase and S-adenosylhomocysteine hydrolase, is also administered.

REFERENCES:
patent: 4680299 (1987-07-01), Hesson
patent: 0 601 191 (1994-06-01), None
patent: 0 721 942 (1996-07-01), None
patent: WO 2000054003 (2000-08-01), None
patent: WO 2002053138 (2002-07-01), None
Nakazato Yoshisuke, “Tetracyclic Quinoline Derivative”, Patent Abstracts of Japan, vol. 1998, No. 14, Dec. 31, 1998.

Affiliated with

Also associated with

Rating

Dihydroorotate dehydrogenase inhibitors for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dihydroorotate dehydrogenase inhibitors for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dihydroorotate dehydrogenase inhibitors for the treatment of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3408248